Danaher Corporation is an American globally diversified conglomerate founded by brothers Stephen and Mitchell Rales in 1984. Headquartered in Washington, D.C., the company designs, manufactures, and markets medical, industrial, and commercial products and services.
Company profile
Ticker
DHR
Exchange
Website
CEO
Rainer Blair
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Roper • Fortive • Ametek • Sensata Technologies Holding • Keysight • MKS Instruments • Cognex • Hurco Companies • Sypris Solutions • Mesa Laboratories ...
Former names
DMG INC
SEC CIK
Corporate docs
Subsidiaries
AB Sciex Finance B.V. • AB Sciex LLC • AB Sciex Pte. Ltd. • Abcam Limited • Alaska Blocker Corp. • Aldevron LLC • BC Distribution B.V. • Beckman Coulter Biomedical GmbH • Beckman Coulter Biotechnology (Suzhou) Co., Ltd. • Beckman Coulter Canada LP ...
IRS number
591995548
DHR stock data
Latest filings (excl ownership)
IRAN
Disclosure regarding Iran Threat Reduction and Syria Human Rights Act
21 Feb 24
10-K
2023 FY
Annual report
21 Feb 24
8-K
Departure of Directors or Certain Officers
14 Feb 24
8-K
Danaher Reports Fourth Quarter and Full Year 2023 Results
30 Jan 24
8-K
Results of Operations and Financial Condition
8 Jan 24
8-K
Danaher Reports Third Quarter 2023 Results
23 Oct 23
10-Q
2023 Q3
Quarterly report
23 Oct 23
8-K
Entry into a Material Definitive Agreement
2 Oct 23
8-K
Entry into a Material Definitive Agreement
19 Sep 23
8-K
Other Events
12 Sep 23
Transcripts
DHR
Earnings call transcript
2023 Q4
30 Jan 24
DHR
Earnings call transcript
2023 Q3
24 Oct 23
DHR
Earnings call transcript
2023 Q2
25 Jul 23
DHR
Earnings call transcript
2023 Q1
25 Apr 23
DHR
Earnings call transcript
2022 Q4
24 Jan 23
DHR
Earnings call transcript
2022 Q3
20 Oct 22
DHR
Earnings call transcript
2022 Q2
21 Jul 22
DHR
Earnings call transcript
2022 Q1
21 Apr 22
DHR
Earnings call transcript
2021 Q4
27 Jan 22
DHR
Earnings call transcript
2021 Q3
21 Oct 21
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q3 2023
77.2% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 2040 |
Opened positions | 191 |
Closed positions | 147 |
Increased positions | 804 |
Reduced positions | 734 |
13F shares | Current |
---|---|
Total value | 139.64 tn |
Total shares | 571.15 mm |
Total puts | 2.76 mm |
Total calls | 3.12 mm |
Total put/call ratio | 0.9 |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 55.94 mm | $13.88 tn |
BLK Blackrock | 49.25 mm | $12.22 tn |
STT State Street | 27.00 mm | $6.70 tn |
Wellington Management | 24.93 mm | $6.19 tn |
FMR | 21.56 mm | $5.35 tn |
MS Morgan Stanley | 19.12 mm | $4.74 tn |
T. Rowe Price | 14.98 mm | $3.68 tn |
Capital International Investors | 14.62 mm | $3.63 tn |
Geode Capital Management | 13.34 mm | $2.93 tn |
JPM JPMorgan Chase & Co. | 9.23 mm | $2.29 tn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
1 Mar 24 | Gutierrez-Ramos Jose-Carlos | Common Stock | Grant | Acquire A | No | No | 0 | 2,932 | 0.00 | 12,958 |
1 Mar 24 | Gutierrez-Ramos Jose-Carlos | Employee stock option Common Stock | Grant | Acquire A | No | No | 255.87 | 6,979 | 1.79 mm | 6,979 |
1 Mar 24 | Gutierrez-Ramos Jose-Carlos | Employee stock option Common Stock | Grant | Acquire A | No | No | 255.87 | 16,285 | 4.17 mm | 16,285 |
1 Mar 24 | Ellis Brian W | Employee stock option Common Stock | Grant | Acquire A | No | No | 255.87 | 12,795 | 3.27 mm | 12,795 |
1 Mar 24 | McGrew Matthew | Employee stock option Common Stock | Grant | Acquire A | No | No | 255.87 | 20,937 | 5.36 mm | 20,937 |
1 Mar 24 | Christopher Paul Riley | Employee stock option Common Stock | Grant | Acquire A | No | No | 255.87 | 11,632 | 2.98 mm | 11,632 |
1 Mar 24 | Christopher Bouda | Common Stock | Grant | Acquire A | No | No | 0 | 978 | 0.00 | 7,542 |
1 Mar 24 | Christopher Bouda | Employee stock option Common Stock | Grant | Acquire A | No | No | 255.87 | 2,327 | 595.41 k | 2,327 |
News
Danaher's Options Frenzy: What You Need to Know
15 Mar 24
Here's How Much $1000 Invested In Danaher 5 Years Ago Would Be Worth Today
15 Mar 24
Top 7 Biotech Stock Winners As Weight Loss Drug Battle Escalates: Goldman Sachs Names Best Picks
13 Mar 24
$1000 Invested In Danaher 10 Years Ago Would Be Worth This Much Today
28 Feb 24
Danaher's Spun-Off Company Veralto Is "Next High-Quality Serial Compounder" - Analyst
27 Feb 24
Press releases
Danaher to Present at TD Cowen Health Care Conference
27 Feb 24
DANAHER ALERT: Bragar Eagel & Squire, P.C. is Investigating Danaher Corporation on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
25 Feb 24
Danaher Commits to Set Science-Based, Net-Zero Greenhouse Gas Emission Reduction Targets
22 Feb 24
Danaher Announces Quarterly Dividend
21 Feb 24
Danaher Launches Collaboration with Cincinnati Children's Hospital Medical Center Aiming to Improve Patient Safety in Early Drug Development
5 Feb 24